The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...

Viking Therapeutics Inc.’s worst stock drop in nine years has handed traders betting against the company a gain big enough to ...

Viking Therapeutics Inc. plunged in early trading on Tuesday after its experimental obesity pill disappointed in a mid-stage ...

Mizuho's Jared Holz joins 'Fast Money' to talk Viking Therapeutics' massive stock drop on new obesity pill data.

The company is the latest facing historic losses as pharmaceutical firms compete to develop a weight-loss pill.

The results could reinforce the dominance of Eli Lilly and Novo Nordisk in the booming market for weight loss and diabetes ...

We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...

Shares of Viking Therapeutics VKTX plunged 42% yesterday after it reported top-line data from the phase II VENTURE-Oral ...

Viking Therapeutics' stock drops 40% despite strong Phase 2 weight-loss drug results. See here to know why I remain ultra bullish on VKTX stock.

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

Viking Therapeutics (VKTX) shares crashed nearly 29% in todays trade after the companys much-anticipated weight-loss pill ...

The clinical-stage biotech, closely watched by some because of its investigational weight-loss drug VK2735, saw its share ...